Advances and controversies in the management of early stage non-small cell lung cancer

Angel Cilleruelo-Ramos, Esther Cladellas-Gutiérrez, Carolina de la Pinta, Laura Quintana-Cortés, Paloma Sosa-Fajardo, Felipe Couñago, Xabier Mielgo-Rubio, Juan Carlos Trujillo-Reyes

ORCID number: Angel Cilleruelo-Ramos 0000-0002-1872-0714; Esther Cladellas-Gutiérrez 0000-0001-7379-0443; Carolina de la Pinta 0000-0002-5425-3471; Laura Quintana-Cortés 0000-0002-0990-3192; Paloma Sosa-Fajardo 0000-0002-0130-321X; Felipe Couñago 0000-0001-7233-0234; Xabier Mielgo-Rubio 0000-0002-0985-6150; Juan Carlos Trujillo-Reyes 0000-0002-3370-0869.

Author contributions: All authors wrote the paper.

Conflict-of-interest statement: No conflict of interest.

Country/Territory of origin: Spain

Specialty type: Oncology

Provenance and peer review: Unsolicited article; Externally peer reviewed.

Peer-review model: Single blind

Peer-review report's scientific quality classification
Grade A (Excellent): A
Grade B (Very good): 0
Grade C (Good): 0
Grade D (Fair): 0
Grade E (Poor): 0

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers.

Angel Cilleruelo-Ramos, Department of Thoracic Surgery, Clinic Universitary Hospital, Valladolid 47005, Spain
Angel Cilleruelo-Ramos, Department of Surgery, Universidad de Valladolid, Valladolid 47001, Spain
Esther Cladellas-Gutiérrez, Juan Carlos Trujillo-Reyes, Department of Thoracic Surgery, Hospital de la Santa Creu i Sant Pau, Barcelona 08029, Spain
Carolina de la Pinta, Department of Radiation Oncology, Hospital Universitario Ramón y Cajal, Madrid 28034, Spain
Laura Quintana-Cortés, Department of Medical Oncology, Hospital Don Benito-Villanueva, Badajoz 06400, Spain
Paloma Sosa-Fajardo, Department of Radiation Therapy, Complejo Hospitalario Universitario, Santiago de Compostela, La Coruña 15706, Spain
Felipe Couñago, Department of Radiation Oncology, Hospital Universitario Quirónsalud Madrid, Madrid 28223, Spain
Felipe Couñago, Department of Radiation Oncology, Hospital La Luz, Madrid 28223, Spain
Felipe Couñago, Department of Medicine, School of Biomedical Sciences, Universidad Europea Madrid, Madrid 28223, Spain
Xabier Mielgo-Rubio, Department of Medical Oncology Unit, Hospital Universitario Fundación Alcorcón, Madrid 28922, Spain
Juan Carlos Trujillo-Reyes, Department of Surgery, Universitat Autònoma, Barcelona 08029, Spain

Corresponding author: Angel Cilleruelo-Ramos, MD, PhD, Surgeon, Department of Thoracic Surgery, Clinic Universitary Hospital, Ramón y Cajal 3, Valladolid 47005, Spain.
ancillera@hotmail.com

Abstract
Complete resection continues to be the gold standard for the treatment of early-stage lung cancer. The landmark Lung Cancer Study Group trial in 1995 estab-
INTRODUCTION

Complete resection continues to be the gold standard for the treatment of early-stage lung cancer. The landmark Lung Cancer Study Group trial in 1995 established lobectomy as the minimum intervention necessary for the management of early-stage non-small cell lung cancer (NSCLC), as it was associated with lower recurrence and metastasis rates than sublobar resection and lower postoperative morbidity and mortality than pneumonectomy[1]. The development of lung-sparing techniques (e.g., sleeve resection with vascular and/or bronchial reconstruction) has reduced the number of pneumonectomies performed and with this the risk of adverse outcomes, as the proportion of pneumonectomies is a quality indicator in thoracic surgery[2].

While lobectomy remains the gold standard for the treatment of early-stage NSCLC, there is a growing tendency to perform sublobar resection in selected cases, as, depending on factors such as tumor size, histologic subtype, lymph node involvement, and resection margins, it can produce similar oncological results to lobectomy[3]. Two randomized clinical trials comparing lobectomy and sublobar resection are currently underway: The United States Cancer and Leukemia Group B trial (CALGB 140503) and the Japanese JCOG0802/WJOG4607L trial[5]. The results so far have shown no significant differences in postoperative morbidity or mortality, but as discussed in greater detail below, data on survival and pulmonary function are pending.

The use of minimally invasive techniques for the surgical treatment of early-stage NSCLC has increased in recent years. Video-assisted thoracoscopic surgery (VATS) is the current procedure of choice for most resections in this setting. A recent nationwide cohort study conducted in Spain reported that over 50% of recent anatomic lung resections had been performed by VATS[6]. The main advantages of VATS compared with open surgery are decreased postoperative pain, fewer postoperative complications, and in some cases even, better oncological outcomes. There are, however, substantial geographic variations in the use of VATS.

Key Words: Video-assisted thoracoscopic surgery; Sublobar resection; Radiofrequency ablation; Stereotactic radiosurgery; Early stage; Lung cancer

©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
Advances in VATS techniques and the design of specific surgical material have led to a progressive reduction in the number of incisions required. Most thoracic surgeons now use between one and three incisions and describe similar oncological results\[^{6,7}\]. Subxiphoid VATS is another minimally invasive technique associated with good outcomes when performed by teams with extensive experience in VATS; it has been linked to a lower incidence of postoperative neuropathic pain\[^{8}\].

The increasing adoption of VATS has favored its use in more locoregionally advanced lung cancers. Data from large series of angio-bronchoplastic or extended lung resections performed by experienced thoracic surgeons show similar outcomes to thoracotomy\[^{9}\].

Good outcomes have also been described with robotic-assisted thoracoscopic surgery in the setting of anatomic resections, although the cost-effectiveness of the technique is not so clear\[^{10}\].

As we discuss below, alternative treatments such as stereotactic body radiotherapy (SBRT) and radiofrequency ablation (RFA) can also produce good outcomes in inoperable patients or patients who refuse surgery.

**ROLE OF SUBLOBAR RESECTION IN LUNG CANCER**

Anatomic sublobar resections have produced comparable oncological results to lobectomy in the treatment of tumors < 2 cm without nodal involvement or distant metastasis\[^{11}\]. These favorable results have led to an increased use of segmentectomy, which, depending on tumor stage and resection margins, can produce similar oncological results to lobectomy in selected patients\[^{12}\].

Anatomic segmentectomy is oncologically more valuable than atypical (wedge) resection in early-stage cancer as it permits the performance of hilar and mediastinal lymph node dissection\[^{13}\].

Its main advantage, however, is its parenchyma-sparing effect, which results in better postoperative respiratory function than lobectomy. In view of the above, anatomic sublobar resection can be considered an appropriate treatment for patients with compromised respiratory function unable to tolerate standard lobectomy. Patients considered to be at high operative risk include patients with FEV\(_1\) < 50% or DLCO < 50% and elderly patients with impaired lung function, pulmonary hypertension, and poor left ventricular function\[^{14,15}\].

Compared with lobectomy, VATS sublobar resection has been linked to shorter hospital stays and drainage times, a lower incidence of supraventricular arrhythmia, and fewer postoperative respiratory complications\[^{11}\].

In certain cases, anatomic segmentectomy involves a higher risk of air leakage when electrocautery is used for intersegmental plane dissection (as reported by several Japanese groups)\[^{5,13}\]. Air leakage is not common when absorbable sutures are used, which is the case in most lung resections.

The only randomized prospective trial to compare lobectomy and sublobar resection in T1N0M0 lung cancer (the Lung Cancer Study Group trial) concluded that patients treated with sublobar resection had a higher risk of locoregional recurrence and death\[^{1}\]. It should be noted, however, that these results were published in 1995 and that lung tumors are now diagnosed earlier.

Several retrospective studies published since 2000 have reported good oncological outcomes in patients with small peripheral tumors (stage I and < 2 cm) treated with segmentectomy\[^{13,16-19}\].

As mentioned, the ongoing CALGB\[^{4}\] and Japanese\[^{5}\] trials have not detected any differences between lobectomy and sublobar resection for postoperative morbidity or mortality, but survival and pulmonary function outcomes are not yet available\[^{4,13,20}\].

Thus, it remains to be determined whether segmentectomy is a valid alternative to lobectomy for the treatment of early-stage NSCLC in patients fit for both procedures\[^{4,5}\].

**POSTRESECTION ADJUVANT THERAPY IN NSCLC**

Thirty percent of lung cancer patients have early-stage disease when diagnosed. The standard treatment is surgery, followed or not by chemotherapy with or without radiotherapy.
Data from retrospective series show that less invasive surgical procedures result in fewer complications, allowing earlier initiation of chemotherapy, but do not appear to have an impact on overall survival (OS).

Postoperative radiotherapy in stage I and II NSCLC is indicated for patients with positive margins. According to the recent results of the phase III LUNG ART trial, postoperative radiotherapy did not have any beneficial effects in patients with pathologic mediastinal involvement (N2), in addition, it induced high levels of toxicity. Chemotherapy, however, was associated with a 5.4% increase in OS at 5 years, regardless of age [hazard ratio (HR) = 0.89]. Chemotherapy is indicated for resected stage II and IIIA NSCLC[21], but its use in stage I disease is more controversial. The standard treatment is four cycles of doublet cisplatin-based chemotherapy. The only clinical trial to investigate the use of carboplatin in this setting reported negative results[22]. Survival outcomes, however, are poor, mainly because of high rates of distant recurrence. Five-year OS rates range from 73% for stage IB disease to 65% for stage IIA disease, 56% for stage IIB disease, and 41% for stage IIIA disease[23]. It is therefore important to continue to explore new treatments and prognostic and predictive biomarkers.

Attempts to improve treatment outcomes with the addition of antiangiogenics[24] or vaccine-based therapy[25] have been unsuccessful. The potential benefits of immunotherapy are being investigated, as good results have been reported for adjuvant immunotherapy in more advanced stages of disease and other types of tumor [26]. Ongoing trials include PEARLS (pembrolizumab), BR31 (durvalumab), ANVIL (nivolumab), Impower 010 (atezolizumab), and Canopy-A (canakinumab). No results, however, are available yet. Immunotherapy, both alone and combined with chemotherapy, has shown promising results in the current setting. Chem-immunotherapy has significantly improved complete and major pathological responses in NSCLC (by approximately 36% and 65%, respectively) and has also led to downstaging in over 70% of patients[26,27]. It remains to be determined whether immunotherapy is more effective as a neoadjuvant or adjuvant treatment[28].

Agents targeting driver mutations are being investigated in multiple trials, but results are still pending. We do have results from the ADAURA trial, where patients with completely resected EGFR mutation–positive NSCLC, regardless of whether or not they had received prior chemotherapy, were randomized to receive osimertinib [a third-generation tyrosine-kinase inhibitor (TKI)] or placebo for 3 years. The progression-free survival (PFS) outcomes for patients with stage II and IIIA disease in the osimertinib group were unprecedented, with an HR for disease recurrence or death of 0.17. In addition, the benefits were observed in all the subgroup analyses. The adverse events were to be expected based on the experience with this drug. Osimertinib was also associated with a reduction in brain recurrences (HR = 0.18)[29]. These results were sufficient for the United States Food and Drug Administration to approve osimertinib as an adjuvant treatment for NSCLC with EGFR mutations. Recent results from another trial showed that icotinib, a first-generation TKI, improved PFS (HR = 0.36) in patients with resected stages II and IIA disease; results on OS have not been published yet[30]. Nonetheless, in the CTONG trial of adjuvant treatment with gefitinib, the improvement observed for PFS was not carried over to OS, reflecting previous findings for other targeted therapies. It remains to be seen whether osimertinib will achieve a survival benefit in the ADAURA trial.

Little has been reported on the use of biomarkers in this setting, as they were not a requirement in most of the trials conducted to date. Thus, the potential values of BRCA1 and of ERCC1 and thymidylate synthase were not validated in the respective SCAT and ITACA trials. Contradictory results have been reported for the prognostic value of PDL-1 expression and tumor mutational burden[31-33]. Nonetheless, next-generation sequencing is a promising strategy for the detection of residual disease after surgery[34,35]. A recent meta-analysis showed that residual molecular disease detected by circulating tumor DNA analysis after complete resection was associated with a higher risk of recurrence and death.

Despite the available evidence, treatment should always be individualized, with careful assessment of risks and benefits, particularly in the current scenario of COVID-19[36].

**SBRT IN EARLY-STAGE LUNG CANCER**

SBRT is a high-precision technique that delivers high doses of radiation over a short period of time[37]. Conceptually derived from cranial stereotactic radiosurgery, it is...
now used in multiple anatomic locations. It is the treatment of choice for early-stage lung cancer in medically inoperable patients or patients who refuse surgery, with a 5-year local control rate of 90%.[38] It improves survival in older patients and reduces the number of untreated patients. When SBRT is not feasible, hypofractionated radiotherapy is preferred to conventionally fractionated schedules.[39] Acute toxicity is rare in SBRT, and includes mild fatigue 1-2 wk after treatment; quality of life is rarely affected.[40] The risk of severe toxicity is low[41], and the most common adverse effect is decreased lung capacity. SBRT can be highly toxic in patients with a history of interstitial lung disease and its use should be assessed by a multidisciplinary committee. Late adverse effects include pain, rib fractures, dyspnea, and ventricular tachycardia.[38] Other effects are esophagitis, epithelitis, and brachial plexopathy. Complications are largely influenced by tumor location and size, radiation dose and target volume.[42]. Pathological confirmation is not always possible, and some authors have suggested that up to 16% of lung nodules may be benign[4].

SBRT has certain technical characteristics that need to be taken into account when planning and administering treatment. Four-dimensional computed tomography (CT) is recommended for preoperative simulation, and multiple beams or arcs should be used for planning purposes as they help limit toxicity.[43].

Dose schedules for peripheral tumors vary, but mostly consist of 3-8 fractions of 7.5-20 Gy each; results for a dose of 54 Gy in 3 fractions include a 3-year local control rate of 91%, a 3-year disseminated failure rate of 22%[44], a 5-year local control rate of 80%, and a 5-year local control rate of 31%.[41]. A phase II trial comparing 30 Gy in 1 fraction and 60 Gy in 3 fractions showed 2-year survival rates of 71% and 61%, respectively, with no differences in toxicity.[45]. On comparing 34 Gy in 1 fraction and 48 Gy in 4 fractions, Nagata et al.[46] found OS rates of 61% and 78%, respectively, and no differences in survival, primary tumor control, or toxicity. In their meta-analysis of 34 observational studies involving 2597 patients, Zhang et al.[47] determined that the most beneficial dose regimens were those that achieved a biologically equivalent dose of 83.3-146 Gy.[47].

Centrally located tumors are tumors located within 2 cm, in any direction, of a critical mediastinal structure, such as the bronchial tree, esophagus, heart, brachial plexus, major vessels, spinal cord, phrenic nerve, and recurrent laryngeal nerve. SBRT is not suitable for ultracentral tumors, but hypofractionated schedules consisting of 6-15 fractions could be considered.[48]. Risk-adapted schedules have achieved high local control rates and limited toxicity. Evidence to date shows a 5-year OS rate of 50% and a local control rate of 93%.[49,50]. A systematic review of SBRT efficacy and toxicity in centrally located NSCLC showed similar local control and survival rates to those achieved in peripheral tumors.

Three randomized clinical trials have compared SBRT and surgery, although they had problems with accrual. A pooled analysis of the STARS and ROSEL trials showed comparable 3-year recurrence-free survival. Results from the ACOSOG Z4099 trial have not been reported. In the RTOG 0813 trial, 100 medically inoperable patients with central tumors were treated with 50-60 Gy in 5 fractions on alternating days. This resulted in 2-year local control, OS, and PFS rates of 88%, 70%, and 53%, respectively; 15 patients experienced grade 3 or higher toxicity (grade 3, 10 patients; grade 4, one patient; and grade 5, four patients). The standard treatment for patients with operable tumors is surgery, lobectomy, and mediastinal lymph node dissection. The RTOG 0236 [41] and 0915[47] trials showed a 3-year OS rate of 56% over a median follow-up of 4 years and a 5-year OS rate of 40%. The local control and 3-year survival rates were 87.3% and 59.9%, respectively. High recurrence rates, however, were observed in the SBRT group during follow-up.[51,52]. Results from the VALOR, SABRTooth, RTOG 3502, and STABLE-MATES trials are pending (Table 1).

When used to treat multiple synchronous tumors vs solitary tumors, SBRT offers similar local control and toxicity rates and worse survival rates.[53] The role of SBRT is being investigated in T3-4N0M0 tumors with schedules of 8-10 Gy per fraction in 8-10 fractions. Two-year local control rates of 68%-73.2% have been described.[54-56]. A recent study demonstrated that SBRT after contralateral pneumonectomy was safe. Arifin et al.[57] analyzed 59 studies with a mean follow-up of 25.4 mo and found a mean 1-year OS rate of 80.6%, a 2-year local control rate of 89.4%, and a grade ≥ 3 rate of 13.2%.

RFA IN EARLY-STAGE NSCLC

RFA is a minimally invasive CT-guided procedure originally approved for use in liver
tumors. It is a percutaneous technique that consists of applying an alternating current (420-500 kHz) to the tumor tissue, resulting in high temperatures (> 70 °C) that cause tissue necrosis and protein denaturation.[58]

Because air is a poor conductor of electricity and a good thermal insulator, the lung is theoretically an ideal site for the application of RFA as the surrounding parenchyma is barely affected.[59] The use of RFA to treat lung tumors was first described by Dupuy et al.[60] in 2000.

The main advantages of RFA over surgery are that it is minimally invasive (percutaneous technique performed with local anesthesia), can be administered on an outpatient basis or under 24-h hospitalization, and does not require thoracotomy[59].

The use of RFA is limited to the treatment of lesions < 3 cm located in the outer two-thirds of the lung parenchyma. Tumor size affects the homogeneity of the temperature distribution within the lesion. Tumors > 3 cm require the use of several overlapping electrical fields to achieve a high enough temperature, and this increases the risk of complications. As with surgery, a margin of healthy parenchymal tissue must be included in the radiofrequency field, but this is difficult to achieve because of the

---

### Table 1: Studies analyzing surgery and stereotactic body radiotherapy in non-small cell lung cancer

| Ref. | Type | Surgery-RT, No. | Surgery-RT, Local failure | Surgery-RT, PFS | Surgery-RT, OS | Surgery-RT, Toxicity | LoE |
|------|------|----------------|--------------------------|----------------|---------------|---------------------|-----|
| Grills et al.[74], 2010 | R | 69 wedge resection; 58 SBRT; Unfit for lobectomy | 20%-4% (P = 0.07) | 65% vs 77% (P = 0.37) | 87% vs 72% (P = 0.01) | Readmission 10%; Pneumonitis 2%; Fracture 11% | 3 |
| Varlotto et al.[75], 2013 | R | 48 sublobar resection +132 lobectomy; 137 SBRT | At 5 yr 18.8% lobectomy vs SBRT 12.2% (P = 0.382); Resection 7.1% | No differences (P = 0.378) | At 5 yr lobectomy vs SBRT 33.7%; Resection 86.3% (P = 0.04, P = 0.003) | 3 |
| Verstegen et al.[76], 2013 | R | 64 VATS; 64 SBRT; 54% inoperable | At 3 yr 3.1% vs 3.6% (P = 0.04) | 79.7% vs 75% | 76.9% vs 90.8% (P = 0.83) | 23.4% vs 6.3% G ≥ 3 (P = 0.03) | 3 |
| Matsuo et al.[77], 2014 | R | 53 sublobar resection; 53 SBRT | At 5 yr 14.1% vs 28.3% (P = 0.059) | 55.6% vs 40.4% (P = 0.124) | | 3 |
| Zheng et al.[78], 2014 | MA | 11921; 7071 surgery; 4650 SBRT | At 1 yr 93% lobectomy vs 91.5% sublobar resection vs 96.3% SBRT. At 3 yr 85% vs 78.4% vs 87.8%. At 5 yr 80% vs 63.4% vs 83.9% (P = 0.45) | At 1 yr 93.5% lobectomy vs 90.3% sublobar resection vs 87.1% SBRT. At 3 yr 82.9% vs 82.1% vs 65.8%. At 5 yr 74.8% vs 71.2% vs 65.8% (P = 0.46) | At 1 yr 92.5% lobectomy vs 93.2% sublobar resection vs 83.4% SBRT. At 3 yr 77.9% vs 80.7% vs 56.6%. At 5 yr 66.1% vs 71.7% vs 41.2% HR = 0.52, 95%CI: 0.2-1.36 for lobectomy and HR = 0.49, 95% CI: 0.19-3.1 for sublobar resection | 1 |
| Yu et al.[79], 2015 | R | 1078; 711 surgery; 367 SBRT | At 2 yr 77.7% vs 59.9% (P = 0.01) | | Acute 54.9% vs 7.9% (P = 0.001). Chronic 73.9% vs 69.7% (P = 0.31) | 3 |
| Rosen et al.[80], 2016 | R | 1781 lobectomy; 1781 SBRT | At 5 yr 59% vs 29%; 58% vs 40% for patients who refused surgery (P = 0.010) | | | 3 |
| Ma et al.[81], 2016 (adjusted for operable patients) | MA | 6969; 3436 VATS; 4433 SBRT | No differences (P = 0.378) | No differences HR = 2.02, 95% CI: 0.45-3.07 (P = 0.36) | | 2 |
| Deng et al.[82], 2017 | MA | 13598 | No differences (P = 0.453) | At 3 yr 68.1% vs 47.7% (P < 0.001) | | 1 |
| Grills et al.[74], 2010 | P. III | 222 Lobectomy; 254 SBRT | At 5 yr 5% vs 8% (P = 0.388) | At 5 yr 72% vs 53% (P = 0.018) | At 5 yr 78% vs 61% (P = 0.006) | | 1 |
| Ackerson et al.[83], 2018 | R | 151 surgery; 70 SBRT | At 3 yr 10% vs 15% (P = 0.71) | 42% vs 29% (P = 0.004) | At 3 yr 63% vs 35% (P < 0.001) | 23%-17% | 3 |
| Tamura et al.[84], 2019 | R | 141 surgery; 106 SBRT | Higher for SBRT (P = 0.0082) | At 5 yr 69.7%-50.2% (P = 0.036) | At 5 yr 69.7% vs 50.2% (P = 0.036) | 8.6% surgery; SBRT G ≥ 2 7.5% | 3 |

G: Grade; LoE: Level of evidence; MA: Meta-analysis; P: Phase; OS: Overall survival; RT: Radiotherapy; VATS: Video-assisted thoracoscopic surgery.
thermal insulation effect mentioned above[61-63].

Central lesions carry a higher risk of complications due to their proximity to the bronchial tree, esophagus, and heart. RFA may be less effective when applied to tumors located close to blood vessels with a diameter > 0.3 cm due to what is known as a “heat sink” effect (a cooling effect caused by the constant renewal of blood within the vessel)[59].

The main adverse effects associated with RFA are pneumothorax [the most common complication (11%-67%) following removal of the electrode from the parenchyma], pleural effusion (related to the increase in pleural temperature), hemoptysis, and more rarely, infections, bronchial fistula, and nerve or cardiac injuries.

In a recent meta-analysis comparing RFA and sublobar resection, Chen et al.[59] analyzed four retrospective studies involving 309 patients: 155 treated with RFA and 154 with sublobar resection. The patients who underwent sublobar resection had significantly higher 1- and 3-year OS and PFS rates (97% vs 91% for 1-year OS, 67% vs 52% for 3-year OS, 91% vs 81% for 1-year PFS, and 67% vs 48% for 3-year PFS). Patients in the RFA group had more complications, but they were milder than those seen in the sublobar resection group.

In their prospective phase II trial of 42 patients with inoperable early-stage lung cancer, Falussière et al.[64] concluded that RFA was a well-tolerated technique with 1- and 3-year local control rates of 84.38% and 81.25%, respectively, and comparable OS rates to those achieved with SBRT. Good tolerability has also been described by other authors[65], including Li et al.[61] in their meta-analysis of 1989 patients.

Few studies have compared local treatments (RFA and SBRT), and the little evidence that exists is based on unbalanced, retrospective data. Randomized prospective studies are needed. Authors who have compared RFA and SBRT, however, agree that SBRT should be the technique of choice for inoperable early-stage cancer because of its favorable safety profile and greater survival benefits. RFA, in turn, should be reserved for small tumors not located near vessels or mediastinal structures[66-68].

At the molecular level, hypoxia-inducible factor-1α has been proposed as an independent prognostic marker in the setting of RFA, as high levels have been linked to an increased risk of mortality[69].

In conclusion, RFA may be useful for treating inoperable early-stage lung cancer, in particular tumors < 3 cm located far from the mediastinum and vessels with a diameter > 0.3 cm[70,71]. The poorer outcomes reported for RFA compared with sublobar resection may be due to the lack of randomized, prospective studies comparing the two treatments, as studies to date have included patients who are unfit for surgery, that is older, more frail patients with more comorbidities and as a result a worse prognosis[72,73]

CONCLUSION

Complete resection continues to be the gold standard for the treatment of early-stage lung cancer. Lobectomy remains the gold standard for the treatment of early-stage NSCLC, but there is a growing tendency to perform sublobar resection in selected cases. Alternative treatments such as SBRT and RFA can also produce good outcomes in inoperable patients or patients who refuse surgery.

REFERENCES

1. Ginsberg RJ, Rubinstein LV. Randomized trial of lobectomy vs limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group. Ann Thorac Surg 1995; 60: 615-622; discussion 622-623 [PMID: 7677489 DOI: 10.1016/0003-4975(95)00537-u]
2. Brunelli A. European Society of Thoracic Surgeons Risk Scores. Thorac Surg Clin 2017; 27: 297-302 [PMID: 28647076 DOI: 10.1016/j.thorsurg.2017.03.009]
3. Postmus PE, Kerr KM, Oudkerk M, Senan S, Waller DA, Vansteenkiste J, Escru C, Peters S; ESMO Guidelines Committee. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2017; 28: iv1-iv21 [PMID: 28881918 DOI: 10.1093/annonc/mdx222]
4. Altorki NK, Wang X, Wigle D, Gu L, Darling G, Ashrafii AS, Landreneau R, Miller D, Liberman M, Jones DR, Keenan R, Conti M, Wright G, Veit LJ, Ramalingam SS, Kamel M, Pass HI, Mitchell JD, Stinchcombe T, Vokes E, Kohman LJ. Perioperative mortality and morbidity after sublobar vs lobar resection for early-stage non-small-cell lung cancer: post-hoc analysis of an international, randomised, phase 3 trial (CALGB/Alliance 140503). Lancet Respir Med 2018; 6: 915-924 [PMID: 30442588]
Cilleruelo-Ramos A et al. Early stage lung cancer treatment

DOI: 10.1016/S2221-2600(18)30411-9

5 Suzuki K, Saji H, Aokage K, Watanabe SI, Okada M, Mizusawa J, Nakajima R, Tsuboi M, Nakamura S, Nakamura K, Mitsudomi T, Asamura H; West Japan Oncology Group; Japan Clinical Oncology Group. Comparison of pulmonary segmentectomy and lobectomy: Safety results of a randomized trial. *J Thorac Cardiovasc Surg* 2019; 158: 895-907 [PMID: 31078312 DOI: 10.1016/j.jtcvs.2019.03.096]

6 Embun R, Royo-Crespo I, Recuero Díaz JL; Spanish Video-Assisted Thoracic Surgery Group. Spanish Video-Assisted Thoracic Surgery Group. Method, Auditing, and Initial Results From a National Prospective Cohort of Patients Receiving Anatomical Lung Resections. *Arch Bronconeumol* 2020; 56: 716-724 [DOI: 10.1016/j.arbres.2020.01.005]

7 Perna V, Carvajal AF, Torrecilla JA, Gigirey O. Uniportal video-assisted thoracoscopic lobectomy vs other video-assisted thoracoscopic lobectomy techniques: a randomized study. *Eur J Cardiothorac Surg* 2016; 50: 411-415 [PMID: 27174540 DOI: 10.1093/ejcts/ezw161]

8 Hernández-Arenas LA, Lin L, Yang Y, Liu M, Guido W, Gonzalez-Rivas D, Jiang G, Jiang L. Initial experience in uniporal subxiphoid video-assisted thoracoscopic surgery for major lung resections. *Eur J Cardiothorac Surg* 2016; 50: 1060-1066 [PMID: 27401700 DOI: 10.1093/ejcts/ezw189]

9 Gao HJ, Jiang ZH, Gong L, Ma K, Ren P, Yu ZT, Wei YC. Video-Assisted Vs Thoracotomy Sleeve Lobectomy for Lung Cancer: A Propensity Matched Analysis. *Ann Thorac Surg* 2019; 108: 1072-1079 [PMID: 31691313 DOI: 10.1016/j.athoracsur.2019.04.037]

10 Song KJ, Flores RM. Commentary: Robot-assisted segmentectomy is safe and expensive—What is the debate? *J Thorac Cardiovasc Surg* 2020; 160: 1373-1374 [PMID: 32087955 DOI: 10.1016/j.jtcvs.2020.01.014]

11 Galvez C, Bolufer S, Corcoles JM, Lirio F, Sesma J, Mafe JJ, Cereal J. Sublobar minimally invasive surgery vs. stereotactic ablative radiotherapy for early stage non-small cell lung cancer. *Mini-invasive Surg* 2020; 4: 86

12 Ohtaki Y, Shimizu K. Anatomical thoracoscopic segmentectomy for lung cancer. *Gen Thorac Cardiovasc Surg* 2014; 62: 586-593 [PMID: 24791926 DOI: 10.1007/s11748-014-0409-0]

13 Mimae T, Okada M. Are segmentectomy and lobectomy comparable in terms of curative intent for early stage non-small cell lung cancer? *Gen Thorac Cardiovasc Surg* 2020; 68: 703-706 [PMID: 31691888 DOI: 10.1007/s11748-019-01219-y]

14 Schneider BJ, Daly ME, Kennedy EB, Stiles BM. Stereotactic Body Radiotherapy for Early-Stage Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American Society for Radiation Oncology Evidence-Based Guideline Summary. *J Oncol Pract* 2018; 14: 180-186 [PMID: 29257717 DOI: 10.1200/JOP.2017.028894]

15 Tosi D, Nosotti M, Bonitga G, Mendogni P, Bertolaccini L, Spaggiari L, Brunelli A, Ruffini E, Falcoz PE. Anatomical segmentectomy vs pulmonary lobectomy for stage I non-small-cell lung cancer: patients selection and outcomes from the European Society of Thoracic Surgeons database analysis. *Interact Cardiovasc Thorac Surg* 2021; 32: 546-551 [PMID: 33313840 DOI: 10.1093/icvts/ivaa296]

16 Fan J, Wang L, Jiang GN, Gao W. Sublobectomy vs lobectomy for stage I non-small-cell lung cancer, a meta-analysis of published studies. *Ann Surg Oncol* 2012; 19: 661-668 [PMID: 21769464 DOI: 10.1245/s10434-011-1931-9]

17 Bedetti B, Bertolaccini L, Rocco R, Schmidt J, Solli P, Scarci M. Segmentectomy vs lobectomy for stage I non-small-cell lung cancer: a systematic review and meta-analysis. *J Thorac Dis* 2017; 9: 1615-1623 [PMID: 28740676 DOI: 10.21037/jtd.2017.05.79]

18 Li H, Liu Y, Ling BC, Hu B. Efficacy of thoracoscopic anatomical segmentectomy for small pulmonary nodules. *World J Clin Cases* 2020; 8: 2227-2234 [PMID: 32548153 DOI: 10.12998/wjcc.v8.i11.2227]

19 Charloux A, Quoix E. Lung segmentectomy: does it offer a real functional benefit over lobectomy? *Eur Respir Rev* 2017; 26 [PMID: 29070582 DOI: 10.1183/16000617.0079-2017]

20 Nakamura K, Saji H, Nakajima R, Okada M, Asamura H, Shibata T, Nakamura S, Tada H, Tsuboi M. A phase III randomized trial of lobectomy vs limited resection for small-sized peripheral non-small cell lung cancer (JCOG0802/WJOG4607L). *Jpn J Clin Oncol* 2010; 40: 271-274 [PMID: 19933688 DOI: 10.1093/jjco/hyp156]

21 Burdett S, Pignon JP, Tierney J, Tribodet H, Stewart L, Le Pechoux C, Aupérin A, Le Chevalier T, Chansky K, Crowley J, Rami-Porta R, Asamura H, Eberhardt WE, Nicholson AG, Parmar MK, Souhami RL, J Thorac Cardiovasc Surg* 2016; 156: 703-706 [PMID: 27401700 DOI: 10.1093/ejcts/ezw189]

22 Strauss GM, Herndon JE 2nd, Maddaus MA, Johnstone DW, Johnson EA, Harpole DH, Gillenwater HH, Watson DM, Sugarbaker DJ, Schlisky RL, Vokes EE, Green MR. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. *J Clin Oncol* 2008; 26: 5043-5051 [PMID: 18809614 DOI: 10.1200/JCO.2008.16.4855]

23 Goldstraw P, Chansky K, Crowley J, Rami-Porta R, Asamura H, Eberhardt WE, Nicholson AG,
Groome P, Mitchell A, Bolejack V; International Association for the Study of Lung Cancer Staging and Prognostic Factors Committee, Advisory Boards, and Participating Institutions; International Association for the Study of Lung Cancer Staging and Prognostic Factors Committee Advisory Boards and Participating Institutions. The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer. J Thorac Oncol 2016; 11: 39-51 [PMID: 26762738 DOI: 10.1016/j.jtho.2015.09.009]

24 Wakelee HA, Dahlberg SE, Keller SM, Tester WJ, Gandara DR, Graziano SL, Adjei AA, Leigh NL, Aisner SC, Rothman JM, Patel JD, Sborov MD, McDermott SR, Perez-Soler R, Traylor AM, Butts C, Evans T, Shafqat A, Chapman AE, Kasbari SS, Horn L, Ramalingam SS, Schiller JH; ECOG-ACRIN. Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial. Lancet Oncol 2017; 18: 1610-1623 [PMID: 29129443 DOI: 10.1016/S1470-2045(17)30691-5]

25 Vansteenkiste JF, Cho BC, Vanakasa T, De Pas T, Zielinski M, Kim MS, Jassem J, Yoshimura M, Dahabreh J, Nakayama H, Havel L, Kondo H, Mitsudomi T, Zarogoulidis K, Gladkov OA, Udag K, Tada H, Hoffman H, Bugge A, Taylor P, Gonzalez EE, Liao ML, He J, Pujol JL, Louahed J, Debois M, Brichard V, Debruyne C, Therasse P, Altorki N. Efficacy of the MAGE-A3 immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2016; 17: 822-835 [PMID: 27132212 DOI: 10.1016/S1470-2045(16)00099-1]

26 Remon J, Passigli F, Ahn MJ, Barlesi F, Forde PM, Garon EB, Gettinger S, Goldberg SB, Herbst RS, Horn L, Kubota K, Lu S, Mezquita L, Paz-Ares L, Popet S, Schlapfer KA, Szolles F, Reck M, Adjei AA, Scagliotti GV. Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations. J Thorac Oncol 2020; 15: 914-947 [PMID: 32179179 DOI: 10.1016/j.jtho.2020.03.006]

27 Provencio M, Nadal E, Innis A, García-Campello MR, Casal-Rubio J, Domíne M, Majem M, Rodríguez-Abreu D, Martínez-Martí A, De Castro Carpejo J, Cobo M, López Vivanco G, Del Barco E, Bernabé-Caro V, Viñolas N, Barneto Aranda I, Viteri S, Pereira E, Royuela A, Casarrubios M, Salas Antón C, Parra ER, Wistuba I, Calvo V, Laza-Briviesca R, Romero A, Massuti B, Cruz-Bermúdez A. Neoadjuvant chemotherapy and nivolumab in resectable NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies. Clin Lung Cancer 2018; 19: 463-4643 [PMID: 32609656 DOI: 10.2147/CLM.S240275]

28 Liu J, Blake SJ, Yong MC, Harjupiáhi H, Ngio SF, Takeda K, Young AJ, O'Donnell JS, Allen S, Smyth MW. Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease. Cancer Discov 2016; 6: 1382-1399 [PMID: 27663893 DOI: 10.1158/2159-8290.CD-16-0577]

29 Wu YL, Tsuobi M, He J, John T, Grohe C, Majern M, Goldman JW, Laktionov K, Kim SW, Kate T, Vu HV, Lu S, Lee KY, Akewanlop C, Yu CJ, de Marinis F, Bonanno L, Domíne M, Shepherd FA, Zeng L, Hodge R, Atasoy A, Rukazenkov Y, Herbst RS; ADAURA Investigators. Osimertinib in Non-Small-Cell Lung Cancer (E1505): an open-label, multicentre, randomised, phase 3 trial. Lancet Oncol 2020; 21: 1413-1422 [PMID: 32979984 DOI: 10.1016/S1470-2045(20)30453-8]

30 Liu YT, Hao XZ, Liu DR, Cheng G, Zhang SC, Xiao WH, Hu Y, Liu JF, He M, Ding CM, Zhang L, Wang J, Li H, Dong GL, Zhi XY, Li J, Shi YK. Icotinib as Adjuvant Treatment for Stage II-IIIA Resected Non-Small-Cell Lung Cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial. J Thorac Oncol 2016; 11: 577-586 [PMID: 26843045 DOI: 10.1016/j.jtho.2015.09.009]

31 Ilie M, Long-Mira E, Bence C, Butori C, Lassalle S, Bouhlel L, Fazzalari L, Zahr F, Lalloo S, Washetine K, Moroux J, Vénissac N, Poudenx M, Otto J, Sabourin JC, Harjupiáhi H, Bence C, Butori C, Lassalle S, Bouhlel L, Fazzalari L, Zahr F, Lalloo S, Washetine K, Moroux J, Vénissac N, Poudenx M, Otto J, Sabourin JC, Marquette CH, Hofman V, Hofman P. Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies. Ann Oncol 2016; 27: 147-153 [PMID: 26483045 DOI: 10.1093/annonc/mdv489]

32 Zarie B, Breic L, Buder A, Brandstetter A, Buresch JO, Traint S, Kovanecz T, Stojic V, Perin B, Perker R, Filipits M. PD-1 and PD-L1 Protein Expression Predict Survival in Completely Resected Lung Adenocarcinoma. Clin Lung Cancer 2018; 19: e957-e963 [PMID: 30197262 DOI: 10.1016/j.clcancer.2018.08.014]

33 Owada-Ozaki Y, Muto S, Takagi H, Inoue T, Watanabe Y, Fukuhara M, Yamaura T, Okabe N, Matsumura Y, Hasegawa T, Ohsugi M, Shioy M, Nanamiya H, Imai JI, Isogai T, Watanabe S, Suzuki H. Prognostic Impact of Tumor Mutation Burden in Patients With Completely Resected Non-Small Cell Lung Cancer: Brief Report. J Thorac Oncol 2018; 13: 1217-1221 [PMID: 29654927 DOI: 10.1016/j.jto.2018.04.003]

34 Abosh C, Birkbak NJ, Swanton C. Early stage NSCLC - challenges to implementing ctDNA-based screening and MRD detection. Nat Rev Clin Oncol 2018; 15: 577-586 [PMID: 29968853 DOI: 10.1038/s41571-018-0058-3]

35 Yin JX, Hu WW, Gu H, Fang JM. Combined assay of Circulating Tumor DNA and Protein Biomarkers for early noninvasive detection and prognosis of Non-Small Cell Lung Cancer. J Cancer 2021; 12: 1258-1269 [PMID: 33422424 DOI: 10.7150/jca.49667]

36 Maitland ML, Heyer D, Gombert-Maitland M. Risk of COVID-19 in Patients With Cancer. JAMA Oncol 2020; 6: 1471 [PMID: 32614413 DOI: 10.1001/jamaoncol.2020.2583]

37 Cilleruelo-Ramos A et al. Early stage lung cancer treatment
56 Berriechoa C, Videtic GM, Woody NM, Djemil T, Zhuang T, Stephens KL. Stereotactic Body Radiotherapy for T3NO Lung Cancer With Chest Wall Invasion. Clin Lung Cancer 2016; 17: 595-601 [PMID: 27301539 DOI: 10.1016/j.cllc.2016.04.007]

57 Arifin AJ, Al-Shafa F, Chen H, Boldt RG, Warner A, Rodrigues GB, Palma DA, Louie AV. Is lung stereotactic ablative radiotherapy safe after pneumonectomy? Transl Lung Cancer Res 2020; 9: 348-353 [PMID: 32420074 DOI: 10.21037/tlcr.2020.01.18]

58 Abbas G, Pennathur A, Landreneau RJ, Luketić JD. Radiofrequency and microwave ablation of lung tumors. J Surg Oncol 2009; 100: 645-650 [PMID: 20017162 DOI: 10.1002/jso.21334]

59 Chen S, Yang S, Xu S, Dong S. Comparison between radiofrequency ablation and sublobar resections for the therapy of stage I non-small cell lung cancer: a meta-analysis. PeerJ 2020; 8: e9228 [PMID: 32509468 DOI: 10.7717/peerj.9228]

60 Dupuy DE, Zagoria RJ, Akerley W, Mayo-Smith WW, Kavanagh PV, Safran H. Percutaneous radiofrequency ablation of malignancies in the lung. AJR Am J Roentgenol 2000; 174: 57-59 [PMID: 10628450 DOI: 10.2214/ajr.174.1.1740057]

61 Li G, Xue M, Chen W, Yi S. Efficacy and safety of radiofrequency ablation for lung cancers: A systematic review and meta-analysis. Eur J Radiol 2018; 100: 92-98 [PMID: 29496085 DOI: 10.1016/j.ejrad.2018.01.009]

62 Yuan Z, Wang Y, Zhang J, Zheng J, Li W. A Meta-Analysis of Clinical Outcomes After Radiofrequency Ablation and Microwave Ablation for Lung Cancer and Pulmonary Metastases. J Am Coll Radial 2019; 16: 302-314 [PMID: 30642784 DOI: 10.1016/j.jacr.2018.10.012]

63 Gao Y, Chen J, Zhang J, Sun L, Zhuang Y. Radiofrequency ablation of primary non-small cell lung cancer: A retrospective study on 108 patients. J BUON 2019; 24: 1610-1618 [PMID: 31646816]

64 Palusierre J, Chomy F, Savina M, Deschamps F, Gaboute JY, Renaul A, Bonmefoy O, Laurent F, Meunier C, Bellera C, Mathoulin-Pelissier S, de Baere T. Radiofrequency ablation of stage IA non-small cell lung cancer in patients ineligible for surgery: results of a prospective multicenter phase II trial. J Cardiovasc Surg 2018; 13: 91 [PMID: 29373827]

65 Akhan O, Güler E, Akıncı D, Çiftçi T, Köse İÇ. Radiofrequency ablation for lung tumors: outcomes, effects on survival, and prognostic factors. Diagn Interv Radiol 2016; 22: 65-71 [PMID: 26611111 DOI: 10.5152/dir.2015.14378]

66 Tetta C, Carpenzano M, Alargough ATJ, Alargough M, Londero F, Maessen GJ, Gelsomino S. Non-surgical Treatments for Lung Metastases in Patients with Soft Tissue Sarcoma: Stereotactic Body Radiotherapy (SBRT) and Radiofrequency Ablation (RFA). Curr Med Imaging 2021; 17: 261-275 [PMID: 32819261 DOI: 10.21274/175340561699200819165709]

67 Lam A, Yoshida EJ, Bui K, Fernando D, Nelson K, Abi-Jaoudeh N. A National Cancer Database Analysis of Radiofrequency Ablation vs Stereotactic Body Radiotherapy in Early-Stage Non-Small Cell Lung Cancer. J Vasc Interv Radiol 2018; 29: 1211-1217.e1 [PMID: 30061058 DOI: 10.1016/j.jvir.2018.04.029]

68 Ager BJ, Wells SM, Gruhl JD, Stoddard GJ, Tao R, Kokeny KE, Hitchcock YJ. Stereotactic body radiotherapy vs percutaneous local tumor radiotherapy for early-stage non-small cell lung cancer. Lung Cancer 2019; 138: 6-12 [PMID: 31593894 DOI: 10.1016/j.lungcan.2019.09.009]

69 Wan J, Ling X, Rao Z, Peng B, Ding G. Independent prognostic value of HIF-1α expression in radiofrequency ablation of lung cancer. Oncot Lett 2020; 19: 849-857 [PMID: 31897199 DOI: 10.3892/ol.2019.11330]

70 Hiyoshi Y, Miyamoto Y, Kiyozumi Y, Sawayama H, Eto K, Nagai Y, Iwatsuki M, Iwagami S, Baba Y, Yoshida N, Kawanaka K, Yamashita Y, Baba H. CT-guided percutaneous radiofrequency ablation for lung metastases from colorectal cancer. Int J Clin Oncol 2019; 24: 288-295 [PMID: 30328230 DOI: 10.1007/s10147-018-1357-5]

71 Ambrogi MC, Fanucchi O, Dini P, Melfi F, Davini F, Lucchi M, Massimetti G, Mussi A. Wedge resection and radiofrequency ablation for stage I nonsmall cell lung cancer. Eur Respir J 2015; 45: 1089-1097 [PMID: 25700387 DOI: 10.1183/09031936.00188014]

72 Hiraki T, Gobara H, Iguchi T, Fujiwara H, Matsui Y, Kanazawa S. Radiofrequency ablation for early-stage non-small cell lung cancer. Biomed Res Int 2014; 2014: 152087 [PMID: 24995270 DOI: 10.1155/2014/152087]

73 Iguchi T, Hiraki T, Gobara H, Fujiwara H, Matsui Y, Soh J, Toyooka S, Kiura K, Kanazawa S. Percutaneous radiofrequency ablation of lung cancer presenting as ground-glass opacity. Cardiovasc Intervent Radiol 2015; 38: 409-415 [PMID: 24938905 DOI: 10.1007/s00270-014-0926-x]

74 Grollis IS, Mangona VS, Welsh R, Chmiielewski G, McInerney E, Martin S, Wloch J, Ye H, Kestin KL. Outcomes after stereotactic lung radiotherapy or wedge resection for stage I non-small-cell lung cancer. J Clin Oncol 2010; 28: 928-935 [PMID: 20965181 DOI: 10.1200/JCO.2009.25.0928]

75 Varlotto J, Fakiris A, Flickinger J, Medford-Davis L, Stoddard GJ, Tao R, Kokeny KE, Hitchcock YJ. Stereotactic body radiation therapy for the therapy of stage I non-small cell lung cancer: A retrospective study on 108 patients. J BUON 2019; 24: 1610-1618 [PMID: 31646816]

76 Versteegen NE, Blulier JW, Palma DA, Rodrigues G, Lagerwaard FJ, van der Elst A, Mollenaar R, van Tets WF, Warner A, Joosten JJ, Amir MI, Haasbeek CJ, Smitt EF, Slotman BJ, Senan S. Stage I/II non-small-cell lung cancer treated using either stereotactic ablative radiotherapy (SBRT) or lobectomy by video-assisted thoracoscopic surgery (VATS): outcomes of a propensity score-matched analysis. Ann Oncol 2013; 24: 1543-1548 [PMID: 23425947 DOI: 10.1093/annonc/mdt026]

77 Matsuoka Y, Ager BJ, Wells SM, Gruhl JD, Stoddard GJ, Tao R, Kokeny KE, Hitchcock YJ. Stereotactic body radiotherapy vs percutaneous local tumor radiotherapy for early-stage non-small cell lung cancer. Lung Cancer 2019; 138: 6-12 [PMID: 31593894 DOI: 10.1016/j.lungcan.2019.09.009]
Hiraoka M. Comparison of long-term survival outcomes between stereotactic body radiotherapy and sublobar resection for stage I non-small-cell lung cancer in patients at high risk for lobectomy: A propensity score matching analysis. Eur J Cancer 2014; 50: 2932-2938 [PMID: 25281527 DOI: 10.1016/j.ejca.2014.09.006]

78 Zheng X, Schipper M, Kidwell K, Lin J, Reddy R, Ren Y, Chang A, Lv F, Orringer M, Spring Kong FM. Survival outcome after stereotactic body radiation therapy and surgery for stage I non-small cell lung cancer: a meta-analysis. Int J Radiat Oncol Biol Phys 2014; 90: 603-611 [PMID: 25052562 DOI: 10.1016/j.ijrobp.2014.05.055]

79 Yu JB, Soulos PR, Cramer LD, Decker RH, Kim AW, Gross CP. Comparative effectiveness of surgery and radiosurgery for stage I non-small cell lung cancer. Cancer 2015; 121: 2341-2349 [PMID: 25847699 DOI: 10.1002/cncr.29359]

80 Rosen JE, Salazar MC, Wang Z, Yu JB, Decker RH, Kim AW, Detterbeck FC, Boffa DJ. Lobectomy vs stereotactic body radiotherapy in healthy patients with stage I lung cancer. J Thorac Cardiovasc Surg 2016; 152: 44-54.e9 [PMID: 27131846 DOI: 10.1016/j.jtcvs.2016.03.060]

81 Ma L, Xiang J. Clinical outcomes of video-assisted thoracic surgery and stereotactic body radiation therapy for early-stage non-small cell lung cancer: A meta-analysis. Thorac Cancer 2016; 7: 442-451 [PMID: 27385987 DOI: 10.1111/1759-7714.12352]

82 Deng HY, Wang YC, Ni PZ, Li G, Yang XY, Lin YD, Liu LX. Radiotherapy, lobectomy or sublobar resection? Eur J Cardiothorac Surg 2017; 51: 203-210 [PMID: 28186277 DOI: 10.1093/ejcts/ezw272]

83 Ackerson BG, Tong BC, Hong JC, Gu L, Chino J, Trotter JW, D’Amico TA, Torok JA, Lafata K, Chang C, Kelsey CR. Stereotactic body radiation therapy vs sublobar resection for stage I NSCLC. Lung Cancer 2018; 125: 185-191 [PMID: 30429018 DOI: 10.1016/j.lungcan.2018.09.020]

84 Tamura M, Matsumoto I, Tanaka Y, Saito D, Yoshida S, Kakegawa S, Kumano T, Shimizu Y, Tamamura H, Takenaka T, Takemura H. Comparison Between Stereotactic Radiotherapy and Sublobar Resection for Non-Small Cell Lung Cancer. Ann Thorac Surg 2019; 107: 1544-1550 [PMID: 30458155 DOI: 10.1016/j.athoracsur.2018.10.015]
